Press release
Stockholm, Sweden, January 8, 2024
Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:
42nd Annual J.P. Morgan Healthcare Conference
San Francisco, USA, January 8-11, 2024
Mendus management team will be in San Francisco for business and investor meetings during the J.P, Morgan conference
https://www.jpmorgan.com/about-us/events-conferences/health-care-conference
13th Annual LifeSci Partners Corporate Access Event
San Francisco, USA, January 8-10, 2024
Mendus will take part in the LifeSci Corporate Access investor event
https://lifescievents.com/event/cae2024/
Redeye Theme: Fight Cancer
Stockholm, Sweden, January 24, 2024
Mendus CEO Erik Manting will present the company and take part in a discussion panel
https://www.redeye.se/events/966280/redeye-theme-fight-cancer-2
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting, CEO
E-mail: ir@mendus.com
ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/
Attachment
